Latest Strategic Investment News

DGL Group Limited has issued a corrected FY25 financial presentation, revealing lower EBITDA and NPAT figures due to operational challenges and restructuring costs. Despite revenue growth, the company faces a modified audit opinion on inventory and outlines strategic cost-cutting and growth investments.

Control Bionics Limited has announced a 1-for-5 non-renounceable rights issue to raise up to $2.06 million, aiming to fund the commercial expansion of its NeuroStrip® device and operational growth. The offer is partially underwritten and open to eligible shareholders in Australia and New Zealand.

4DMedical has bolstered its financial footing with a $6 million R&D tax incentive and a $10 million strategic investment, while its XV LVAS® technology gains clinical validation for predicting serious COPD treatment complications.

Lion Selection Group has committed $1 million to Sunshine Metals, increasing its stake to 9.2% as Sunshine advances promising high-grade gold projects in North Queensland.

Mayfield Childcare Limited reported a modest underlying EBITDA loss for the first half of 2025 amid occupancy challenges and acquisition underperformance. The company’s operational overhaul and targeted investments signal a cautious but hopeful recovery trajectory.

HALO Technologies reports a significantly improved half-year net loss and secures verbal FCA approval for its UK platform, while preparing to launch Managed Funds in Australia.

Rewardle Holdings reports a sharp 497% increase in half-year losses amid strategic investments in its MedTech partner CloudHolter and fintech expansions. Despite financial headwinds, the company advances its B2B2C platform with a focus on growth and innovation.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

Spenda Limited reported a 106% surge in revenue to $11.1 million for FY25, driven by acquisitions and expanded services, yet posted a substantial $24.3 million net loss largely due to goodwill impairment. The company’s strategic moves and funding needs highlight a pivotal phase ahead.

Wide Open Agriculture Limited has trimmed its annual loss to $7.09 million while expanding its lupin protein sales pipeline across key international markets and optimizing production in Germany.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.